Mammographic, US, and MR imaging phenotypes of familial breast cancer
Mammographic, US, and MR imaging phenotypes of familial breast cancer
复制标题
DOI：
10.1148/radiol.2461062173
复制
发表时间：
2008-01-01
期刊：
影响因子：
19.7
通讯作者：
Kuhl, Christiane K.
中科院分区：
文献类型：
--
作者：
Schrading, Simone;Kuhl, Christiane K.
前瞻性调查的影像学（钼靶，超声[US]，磁共振[MR]成像）的特点，浸润性和导管内乳腺癌的妇女在familial risk.Materials和方法：伦理委员会的批准和知情同意。乳腺癌在中度增加风险的妇女中，在高家族风险的妇女中，以及在记录的BRCA 1和BRCA 2突变携带者中被确定。所有的癌症进行了研究与乳房X线摄影，美国，和双边动态乳腺MR成像。前瞻性收集并比较不同风险类别女性乳腺癌的影像学表现。结果：68例（平均年龄41.3岁）乳腺癌患者中，76例乳腺癌的影像学特征经双样本Wilcoxon符号秩检验进行比较。乳腺密度对乳腺癌的检出率无影响。不同风险类别的影像学表型不同：64例浸润性癌症中有15例（23%）表现为纤维腺瘤样肿块，无钙化，但在乳腺MR成像中无纤维腺瘤样内部增强或增强动力学。其中，12例（80%）发生在高危女性和BRCA 1突变携带者中。67%（32/48）的高危和突变携带者乳腺癌发生于胸后部（紧邻胸前区）（P
To prospectively investigate the imaging (mammographic, ultrasonographic [US], magnetic resonance [MR] imaging) features of invasive and intraductal breast cancers in women at familial risk.Materials and Methods: Ethics committee approval and informed consent were obtained. Breast cancers were identified in women at moderately increased risk, in women at high familial risk, and in documented BRCA1 and BRCA2 mutation carriers. All cancers were investigated with mammography, US, and bilateral dynamic breast MR imaging. Imaging findings of breast cancer in women in the different risk categories were prospectively collected and compared. With the two-sample Wilcoxon signed rank test, imaging features of cancers were compared.Results: Seventy-six breast cancers were identified in 68 women (mean age, 41.3 years). Mammographic breast density had no influence on detectability of cancers. Imaging phenotypes differed among risk categories: 15 (23%) of 64 invasive cancers appeared as fibroadenoma-like masses without calcifications but without fibroadenoma-like internal enhancement or enhancement kinetics at breast MR imaging. Of those, 12 (80%) occurred in women at high risk and documented BRCA1 mutation carriers. A posterior (immediately prepectoral) location was observed in 67% (32 of 48) of all breast cancers in women at high risk and mutation carriers (P